Shire Stock Price, News & Analysis (NASDAQ:SHPG)

$126.05 +1.02 (+0.82 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$125.03
Today's Range$125.74 - $127.63
52-Week Range$123.73 - $192.15
Volume1.28 million shs
Average Volume1.52 million shs
Market Capitalization$38.11 billion
P/E Ratio8.98
Dividend Yield0.73%
Beta1.41

About Shire (NASDAQ:SHPG)

Shire logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SHPG
CUSIPN/A
Phone353-1429-7700

Debt

Debt-to-Equity Ratio0.55%
Current Ratio0.98%
Quick Ratio0.52%

Price-To-Earnings

Trailing P/E Ratio8.97722419928825
Forward P/E Ratio8.27
P/E Growth0.71

Sales & Book Value

Annual Sales$15.16 billion
Price / Sales2.50
Cash Flow$16.29 per share
Price / Cash7.74
Book Value$95.20 per share
Price / Book1.32

Profitability

Trailing EPS$14.05
Net Income$4.27 billion
Net Margins28.17%
Return on Equity14.75%
Return on Assets6.88%

Miscellaneous

Employees23,906
Outstanding Shares300,890,000

Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire announced a semiannual dividend on Friday, February 16th. Stockholders of record on Friday, March 9th will be given a dividend of $0.8937 per share on Tuesday, April 24th. This represents a dividend yield of 1.33%. The ex-dividend date is Thursday, March 8th. This is an increase from Shire's previous semiannual dividend of $0.15. View Shire's Dividend History.

How were Shire's earnings last quarter?

Shire PLC (NASDAQ:SHPG) issued its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.86 by $0.12. The biopharmaceutical company had revenue of $4.14 billion for the quarter. Shire had a net margin of 28.17% and a return on equity of 14.75%. The company's revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter last year, the company posted $3.37 EPS. View Shire's Earnings History.

When will Shire make its next earnings announcement?

Shire is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Shire.

What guidance has Shire issued on next quarter's earnings?

Shire issued an update on its FY18 earnings guidance on Wednesday, February, 14th. The company provided earnings per share (EPS) guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.02. The company issued revenue guidance of 15.4-15.9 billion, compared to the consensus revenue estimate of $15.47 billion.

Where is Shire's stock going? Where will Shire's stock price be in 2018?

17 analysts have issued 1-year target prices for Shire's shares. Their forecasts range from $150.00 to $245.00. On average, they anticipate Shire's stock price to reach $204.00 in the next twelve months. View Analyst Ratings for Shire.

What are Wall Street analysts saying about Shire stock?

Here are some recent quotes from research analysts about Shire stock:

  • 1. Cantor Fitzgerald analysts commented, "Shire reported 4Q17 results and provided its 2018 financial guidance this morning. The report was mixed relative to expectations. Investors that we spoke with were anticipating a strong 4Q17 with no surprises, but hoping for 2018 consensus sales and EPS that would at least bracket consensus (which did not happen)." (2/14/2018)
  • 2. According to Zacks Investment Research, "The sales of Mydayis did not meet Shire’s expectation while strong performance of Vyvanse, Cinryze and Elaprase continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past one year. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters." (2/6/2018)
  • 3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)

Are investors shorting Shire?

Shire saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 2,421,141 shares, a drop of 34.8% from the January 12th total of 3,712,240 shares. Based on an average daily volume of 1,775,924 shares, the days-to-cover ratio is currently 1.4 days. Approximately 0.8% of the company's shares are sold short.

Who are some of Shire's key competitors?

Who are Shire's key executives?

Shire's management team includes the folowing people:

  • Flemming Ornskov M.D., Chief Executive Officer, Executive Director (Age 59)
  • John Miller, Interim Chief Financial Officer
  • Joanne Cordeiro, Chief Human Resource Officer
  • Andreas Busch Ph.D., Executive Vice President - Head of Research and Development, Chief Scientific Officer (Age 54)
  • Gisele Dion, Chief Accounting Officer, Corporate Controller (Age 51)
  • William Mordan, General Counsel, Company Secretary (Age 47)
  • Howard Mayer M.D., Chief Medical Officer
  • Perry Sternberg, Head - U.S. Commercial (Age 48)
  • Kim Stratton, Head - International Commercial (Age 56)
  • Philip J. Vickers, Head - Research and Development (Age 56)

Who owns Shire stock?

Shire's stock is owned by a number of of retail and institutional investors. Top institutional investors include Boston Partners (0.78%), The Manufacturers Life Insurance Company (0.61%), Maverick Capital Ltd. (0.55%), BlackRock Inc. (0.35%), Rockefeller Financial Services Inc. (0.19%) and ING Groep NV (0.17%). View Institutional Ownership Trends for Shire.

Who sold Shire stock? Who is selling Shire stock?

Shire's stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Maverick Capital Ltd., Jennison Associates LLC, Millennium Management LLC, Deutsche Bank AG, BlackRock Inc., Capital Fund Management S.A. and York Capital Management Global Advisors LLC. View Insider Buying and Selling for Shire.

Who bought Shire stock? Who is buying Shire stock?

Shire's stock was bought by a variety of institutional investors in the last quarter, including Boston Partners, ING Groep NV, FNY Partners Fund LP, Brandywine Global Investment Management LLC, Snow Capital Management LP, Bank of Montreal Can, Delek Group Ltd. and OLD Mission Capital LLC. View Insider Buying and Selling for Shire.

How do I buy Shire stock?

Shares of Shire can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire's stock price today?

One share of Shire stock can currently be purchased for approximately $126.05.

How big of a company is Shire?

Shire has a market capitalization of $38.11 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $14.05 on an earnings per share basis. Shire employs 23,906 workers across the globe.

How can I contact Shire?

Shire's mailing address is 5 Riverwalk Citywest Business Campus, Dublin L2, D24. The biopharmaceutical company can be reached via phone at 353-1429-7700 or via email at [email protected]


MarketBeat Community Rating for Shire (SHPG)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  860 (Vote Outperform)
Underperform Votes:  400 (Vote Underperform)
Total Votes:  1,260
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire (NASDAQ:SHPG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.572.672.70
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $204.00$212.18$212.18$220.91
Price Target Upside: 61.05% upside34.90% upside51.53% upside51.78% upside

Shire (NASDAQ:SHPG) Consensus Price Target History

Price Target History for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/20/2018SunTrust BanksLower Price TargetBuy$190.00MediumView Rating Details
2/20/2018JPMorgan Chase & Co.Reiterated RatingOverweight -> NeutralMediumView Rating Details
2/16/2018Royal Bank of CanadaLower Price TargetOutperform$181.00LowView Rating Details
2/16/2018B. RileyLower Price TargetBuy -> Buy$201.00 -> $181.00LowView Rating Details
2/14/2018Cantor FitzgeraldSet Price TargetBuy$222.00MediumView Rating Details
2/14/2018Sanford C. BernsteinUpgradeMarket Perform -> OutperformMediumView Rating Details
2/5/2018Bank of AmericaBoost Price TargetBuy -> Buy$236.00 -> $237.00HighView Rating Details
1/5/2018CowenSet Price TargetBuy$225.00LowView Rating Details
1/3/2018Piper Jaffray CompaniesReiterated RatingHoldLowView Rating Details
12/20/2017Liberum CapitalReiterated RatingBuy -> HoldMediumView Rating Details
10/30/2017FBR & CoReiterated RatingBuy$201.00N/AView Rating Details
10/8/2017Stifel NicolausReiterated RatingBuy$245.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$196.00MediumView Rating Details
8/11/2017BarclaysDowngradeOverweight -> Equal WeightLowView Rating Details
8/9/2017Jefferies GroupReiterated RatingHold$216.00 -> $206.00LowView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$242.00LowView Rating Details
4/17/2017Goldman Sachs GroupBoost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/3/2016CitigroupReiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Shire (NASDAQ:SHPG) Earnings History and Estimates Chart

Earnings by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ SHPG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018        
2/14/2018n/a$3.86$3.98$4.14 billionViewN/AView Earnings Details
10/27/20179/30/2017$3.64$3.81$3.70 billionViewN/AView Earnings Details
8/3/20176/30/2017$3.53$3.73$3.75 billionViewListenView Earnings Details
5/2/2017Q1 17$3.22$3.63$3.57 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.78 billion$3.81 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.28 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.53 billion$1.58 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
10/29/2010Q3 2010$0.98$1.16ViewN/AView Earnings Details
8/4/2010Q2 2010$0.88$1.03ViewN/AView Earnings Details
4/29/2010Q1 2010$0.84$1.01ViewN/AView Earnings Details
2/19/2010Q4 2009$0.58$1.10ViewN/AView Earnings Details
10/30/2009Q3 2009$0.48$0.49ViewN/AView Earnings Details
8/5/2009Q2 2009$0.47$0.60ViewN/AView Earnings Details
4/30/2009Q1 2009$1.08$1.28ViewN/AView Earnings Details
2/19/2009Q4 2008$1.00$1.01ViewN/AView Earnings Details
10/29/2008Q3 2008$0.87$1.17ViewN/AView Earnings Details
7/31/2008Q2 2008$0.75$0.95ViewN/AView Earnings Details
4/25/2008Q1 2008$0.72$0.74ViewN/AView Earnings Details
2/21/2008Q4 2007$0.64$0.94ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Shire (NASDAQ:SHPG) Earnings Estimates

2018 EPS Consensus Estimate: $15.73
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$3.75$4.01$3.88
Q2 20184$3.68$4.13$3.91
Q3 20184$3.71$4.08$3.85
Q4 20184$3.78$4.37$4.09
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Shire (NASDAQ:SHPG) Dividend Information

Next Dividend:4/24/2018
Annual Dividend:$0.92
Dividend Yield:0.73%
Payout Ratio:6.55% (Trailing 12 Months of Earnings)
6.04% (Based on This Year's Estimates)
5.43% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/16/2018semiannual$0.891.33%3/8/20183/9/20184/24/2018
8/11/2017semiannual$0.150.21%9/7/20179/8/201710/20/2017
2/24/2017$0.773/8/20173/10/20174/25/2017
8/5/2016$0.149/7/20169/9/201610/7/2016
2/11/2016$0.673/9/20163/11/20164/12/2016
7/23/2015$0.139/2/20159/4/201510/2/2015
2/23/2015semiannual$0.570.48%3/11/20153/13/20154/14/2015
8/4/2014semiannual$0.110.09%9/3/20149/5/201410/3/2014
2/20/2014semiannual$0.510.61%3/5/20143/7/20144/8/2014
7/29/2013semiannual$0.090.16%9/4/20139/6/201310/3/2013
2/19/2013semiannual$0.440.92%3/6/20133/8/20134/9/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire (NASDAQ SHPG)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Shire (NASDAQ SHPG) News Headlines

Source:
DateHeadline
FY2019 Earnings Estimate for Shire PLC Issued By SunTrust Banks (SHPG)FY2019 Earnings Estimate for Shire PLC Issued By SunTrust Banks (SHPG)
www.americanbankingnews.com - February 22 at 2:30 PM
Shire Recognizes Rare Disease Day 2018 with Global Initiatives Focused on Reducing the Time to DiagnosisShire Recognizes Rare Disease Day 2018 with Global Initiatives Focused on Reducing the Time to Diagnosis
finance.yahoo.com - February 22 at 8:16 AM
FY2018 EPS Estimates for Shire PLC (SHPG) Decreased by SunTrust BanksFY2018 EPS Estimates for Shire PLC (SHPG) Decreased by SunTrust Banks
www.americanbankingnews.com - February 21 at 11:14 AM
Shire (SHPG) PT Lowered to $190.00 at SunTrust BanksShire (SHPG) PT Lowered to $190.00 at SunTrust Banks
www.americanbankingnews.com - February 20 at 8:26 PM
Reviewing Shire (SHPG) and Novartis (NVS)Reviewing Shire (SHPG) and Novartis (NVS)
www.americanbankingnews.com - February 20 at 4:28 PM
Shire (SHPG) Earns "Neutral" Rating from JPMorgan Chase & Co.Shire (SHPG) Earns "Neutral" Rating from JPMorgan Chase & Co.
www.americanbankingnews.com - February 20 at 4:06 PM
Shire to Present Data at 2018 AAAAI/WAO Joint Congress Demonstrating Commitment to Ongoing Research and Innovation in  Rare Immune ConditionsShire to Present Data at 2018 AAAAI/WAO Joint Congress Demonstrating Commitment to Ongoing Research and Innovation in Rare Immune Conditions
feeds.benzinga.com - February 20 at 9:49 AM
George Soros Just Dumped These 2 Healthcare Stocks. Should You?George Soros Just Dumped These 2 Healthcare Stocks. Should You?
www.fool.com - February 20 at 9:31 AM
Shire (SHPG) Stock Rating Lowered by JPMorgan Chase & Co.Shire (SHPG) Stock Rating Lowered by JPMorgan Chase & Co.
www.americanbankingnews.com - February 19 at 4:12 PM
Shire PLC to Post FY2018 Earnings of $15.23 Per Share, Jefferies Group Forecasts (SHPG)Shire PLC to Post FY2018 Earnings of $15.23 Per Share, Jefferies Group Forecasts (SHPG)
www.americanbankingnews.com - February 19 at 5:22 AM
Q3 2018 EPS Estimates for Shire PLC (SHPG) Reduced by William BlairQ3 2018 EPS Estimates for Shire PLC (SHPG) Reduced by William Blair
www.americanbankingnews.com - February 19 at 4:10 AM
Q1 2018 Earnings Estimate for Shire PLC (SHPG) Issued By B. RileyQ1 2018 Earnings Estimate for Shire PLC (SHPG) Issued By B. Riley
www.americanbankingnews.com - February 19 at 1:44 AM
Shire (SHPG) Given New $181.00 Price Target at Royal Bank of CanadaShire (SHPG) Given New $181.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - February 16 at 9:54 PM
Shire PLC (SHPG) Announces Semiannual Dividend of $0.89Shire PLC (SHPG) Announces Semiannual Dividend of $0.89
www.americanbankingnews.com - February 16 at 6:46 PM
FY2018 EPS Estimates for Shire PLC (SHPG) Reduced by AnalystFY2018 EPS Estimates for Shire PLC (SHPG) Reduced by Analyst
www.americanbankingnews.com - February 16 at 11:18 AM
Shire (SHPG) PT Lowered to $181.00Shire (SHPG) PT Lowered to $181.00
www.americanbankingnews.com - February 16 at 9:52 AM
Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong - NasdaqShire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong - Nasdaq
www.nasdaq.com - February 16 at 8:14 AM
Analysts Set Expectations for Shire PLCs Q1 2018 Earnings (SHPG)Analysts Set Expectations for Shire PLC's Q1 2018 Earnings (SHPG)
www.americanbankingnews.com - February 16 at 7:56 AM
Your Daily Pharma Scoop: Shire Looks Attractive, Omeros Data, Axovant RestructuringYour Daily Pharma Scoop: Shire Looks Attractive, Omeros Data, Axovant Restructuring
seekingalpha.com - February 15 at 5:23 PM
Shire (SHPG) Earns "Buy" Rating from Royal Bank of CanadaShire (SHPG) Earns "Buy" Rating from Royal Bank of Canada
www.americanbankingnews.com - February 15 at 11:18 AM
Head to Head Survey: Avanir Pharmaceuticals (AVNR) versus Shire (SHPG)Head to Head Survey: Avanir Pharmaceuticals (AVNR) versus Shire (SHPG)
www.americanbankingnews.com - February 15 at 8:58 AM
FY2017 Earnings Estimate for Shire PLC Issued By SunTrust Banks (SHPG)FY2017 Earnings Estimate for Shire PLC Issued By SunTrust Banks (SHPG)
www.americanbankingnews.com - February 15 at 7:56 AM
Sanford C. Bernstein Upgrades Shire (SHPG) to "Outperform"Sanford C. Bernstein Upgrades Shire (SHPG) to "Outperform"
www.americanbankingnews.com - February 14 at 9:29 PM
Shire (SHPG) PT Set at $222.00 by Cantor FitzgeraldShire (SHPG) PT Set at $222.00 by Cantor Fitzgerald
www.americanbankingnews.com - February 14 at 9:26 PM
Shire Plc (SHPG) Q4 2017 Results - Earnings Call TranscriptShire Plc (SHPG) Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - February 14 at 3:43 PM
FY2019 EPS Estimates for Shire PLC Lowered by SunTrust Banks (SHPG)FY2019 EPS Estimates for Shire PLC Lowered by SunTrust Banks (SHPG)
www.americanbankingnews.com - February 14 at 2:58 PM
Shire (SHPG) Announces  Earnings Results, Beats Estimates By $0.12 EPSShire (SHPG) Announces Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - February 14 at 11:12 AM
Shire PLC Q4 revenues up 9%; non-GAAP EPS up 18%; updates guidanceShire PLC Q4 revenues up 9%; non-GAAP EPS up 18%; updates guidance
seekingalpha.com - February 14 at 9:27 AM
Shire beats Street 4Q forecastsShire beats Street 4Q forecasts
finance.yahoo.com - February 14 at 9:27 AM
Shire ‍sees slowdown in earnings growth as generic rivals biteShire ‍sees slowdown in earnings growth as generic rivals bite
finance.yahoo.com - February 14 at 9:27 AM
Shire ‍posts 16 pct rise in full-year earnings, sees slower growth in 2018Shire ‍posts 16 pct rise in full-year earnings, sees slower growth in 2018
finance.yahoo.com - February 14 at 9:27 AM
Shire (SHPG) Issues FY18 Earnings GuidanceShire (SHPG) Issues FY18 Earnings Guidance
www.americanbankingnews.com - February 14 at 9:04 AM
Shire plc : Final ResultsShire plc : Final Results
feeds.benzinga.com - February 14 at 7:49 AM
Two Shire pipeline candidates nab special development designationsTwo Shire pipeline candidates nab special development designations
seekingalpha.com - February 13 at 9:32 AM
Shire (SHPG) to Report Q4 Earnings: What's in the Cards?Shire (SHPG) to Report Q4 Earnings: What's in the Cards?
finance.yahoo.com - February 12 at 3:41 PM
Shire (SHPG) to Report Q4 Earnings: Whats in the Cards?Shire (SHPG) to Report Q4 Earnings: What's in the Cards?
www.zacks.com - February 12 at 9:19 AM
Shire PLC (SHPG) Sees Large Decrease in Short InterestShire PLC (SHPG) Sees Large Decrease in Short Interest
www.americanbankingnews.com - February 12 at 4:08 AM
Shire (SHPG) & Collegium Pharmaceutical (COLL) Head-To-Head SurveyShire (SHPG) & Collegium Pharmaceutical (COLL) Head-To-Head Survey
www.americanbankingnews.com - February 10 at 1:14 AM
Shire PLC (SHPG) Given Average Recommendation of "Hold" by BrokeragesShire PLC (SHPG) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 9 at 1:50 PM
Shire (SHPG) Scheduled to Post Earnings on WednesdayShire (SHPG) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - February 7 at 3:46 AM
Health care stocks turn upward as market reboundsHealth care stocks turn upward as market rebounds
www.marketwatch.com - February 6 at 3:40 PM
Zacks Investment Research Upgrades Shire (SHPG) to "Hold"Zacks Investment Research Upgrades Shire (SHPG) to "Hold"
www.americanbankingnews.com - February 6 at 1:56 PM
Royal Bank of Canada Analysts Give Shire (SHPG) a $192.00 Price TargetRoyal Bank of Canada Analysts Give Shire (SHPG) a $192.00 Price Target
www.americanbankingnews.com - February 6 at 10:22 AM
Bank of America Boosts Shire (SHPG) Price Target to $237.00Bank of America Boosts Shire (SHPG) Price Target to $237.00
www.americanbankingnews.com - February 5 at 11:06 AM
Is Shire plc’s (LON:SHP) PE Ratio A Signal To Buy For Investors?Is Shire plc’s (LON:SHP) PE Ratio A Signal To Buy For Investors?
finance.yahoo.com - February 5 at 9:11 AM
Shire (SHPG) Downgraded to "Hold" at ValuEngineShire (SHPG) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 4 at 1:48 PM
Sanofi to Acquire BioverativSanofi to Acquire Bioverativ
finance.yahoo.com - February 1 at 3:39 PM
Shire PLC (SHPG) Expected to Post Quarterly Sales of $4.01 BillionShire PLC (SHPG) Expected to Post Quarterly Sales of $4.01 Billion
www.americanbankingnews.com - February 1 at 2:58 AM
 Brokerages Expect Shire PLC (SHPG) to Announce $3.88 Earnings Per Share Brokerages Expect Shire PLC (SHPG) to Announce $3.88 Earnings Per Share
www.americanbankingnews.com - January 30 at 7:12 PM
AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences PRIM ProgramAB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program
feeds.benzinga.com - January 30 at 8:20 AM

SEC Filings

Shire (NASDAQ:SHPG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Shire (NASDAQ:SHPG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Shire (NASDAQ SHPG) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.